Our study found that ANLN expression was positively associated with TMB or MSI in multiple cancers, including BLCA, which was consistent with the results from the BLCA immunotherapy cohort that patients with higher ANLN level had better immune responses and thus demonstrated longer OS. The gene discussed is ANLN; the disease is bladder transitional cell carcinoma.